Weekly update|Companies|Recruiting|Promote|Post a job

Cerevel Therapeutics

Founded: 2018

Location: Cambridge, MA

Employee range: 200 - 500

Clinical stage: Clin3

Therapy area: Early Parkinson's

Drug types: NEU, ABU, PSY

Lead product: Tavapadon

Product link: https://www.cerevel.com/rd/#pipeline

Funding: $254M stock Aug 2022; $350M stock Jul 2021; $125M stock Apr 2021; $350M Oct 2018

cerevel.com

linkedin.com

job board

Short description:

Neuro

Drug notes:

Also Clin3 late Parkinson's; Emraclidine Clin2 schizophrenia/psychosis; Darigabat Clin2 epilepsy, Clin1 panic disorder; CVL-871 Clin2 dementia-related apathy; CVL-354 Clin1 depression, substance use disorder; CVL-047 Clin0 depression, schizophrenia; 2 undisclosed programs RD schizophrenia/psychosis, Parkinson's

Long description:

Cerevel Therapeutics is understanding the brain to treat neuroscience diseases. Many diseases are caused by malfunctions of neurocircuitry affecting millions of people worldwide. Cerevel is striving to understand why these deficits in neurocircuitry occur and how they can be treated. Using advancements in chemistry, genomics and proteomics, Cerevel is identifying small molecules that target neuronal receptors to normalize neural network function. Cerevel currently has a diverse pipeline with therapies addressing various neurological disorders including Parkinson’s, Epilepsy and Anxiety in pre-clinical and clinical stages.

Jobs:

Principal Scientist, DMPK

Boston, MA|31 days ago

Apply

Senior Manager, Clinical Trial Transparency and Di...

Boston, MA|52 days ago

Main

Contact: recruit@workinbiotech.com